A let-7 KRAS rs712 polymorphism increases colorectal cancer risk
- 358 Downloads
Growing evidence has indicated that polymorphism present in the miRNA binding site of target gene can alter the ability of miRNAs to bind its target gene and modulate the development and progression of cancer. We aimed to investigate the association between let-7 KRAS rs712 polymorphism and the risk of colorectal cancer (CRC). The let-7 KRAS rs712 was analyzed in a case–control study, including 339 CRC patients and 313 age- and sex-matched controls; the relationship between the polymorphism and the clinicopathological features of CRC was also examined. Individuals carrying the let-7 KRAS rs712 TT genotype and T allele had an increased risk of developing CRC (TT vs. GG, adjusted OR = 2.18; 95 % CI, 1.00–4.77; T vs. G, adjusted OR = 1.50; 95 % CI, 1.15–1.96). Stratified analyses revealed that CRC patients with the let-7 KRAS rs712 TT genotype were more likely to have clinical stage III or IV disease (OR = 3.29, 95 % CI, 1.32–8.20) and distant metastasis (OR = 4.70, 95 % CI, 1.81–12.25). These findings provide evidence that the let-7 KRAS rs712 polymorphism may play crucial roles in the etiology of CRC.
KeywordsSingle nucleotide polymorphism Let-7 KRAS Colorectal cancer
This work was supported by National Natural Science Foundation of China (no. 81302149), Natural Science Foundation of the Science and Technology Department of Henan Province (no. 132300410105), the Ph.D. Scientific Research Foundation of Henan University of Science and Technology (no. 09001492).
Conflicts of interest
- 16.Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al. A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol. 2011;22(1):104–9.PubMedCrossRefGoogle Scholar
- 18.Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J. 2010;10(5):458–64.PubMedCrossRefGoogle Scholar
- 20.Li Z H, Pan X M, Han B W, Guo X M, Zhang Z, Jia J, et al. A let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancer. Tumour Biol. 2013Google Scholar